Communicating the Risks of Medicines

Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD The views expressed are those of the author and not necessarily those of the US Food and Drug Administration of the US Government. The author declares no conflict of interest. Reprints: Gerald J. Dal Pan, MD, MHS, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993. E-mail: [email protected]

Administration (probate law) · Drug · Drug administration · Environmental health · Food and drug administration · Government (linguistics) · Pathology · Political science · Epidemiology · Ethics in Clinical Research · Health Systems, Economic Evaluations, Quality of Life · Law · Medicine · Pharmaceutical industry and healthcare · Pharmacology · Public Administration

• Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis

  Christine Y Lu, Robert B Penfold et al.•Medical Care•2018

  Incluir item

• Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors

  Stacie B Dusetzina, Ashley S Higashi et al.•Medical Care•2012

  Incluir item